Posted by Michael Wonder on 11 Jan 2023
UNION therapeutics receives FDA fast track designation for oral orismilast for the treatment of moderate to severe hidradenitis suppurativa
10 January 2023 - Orismilast is a high potency PDE4 inhibitor with broad anti-inflammatory properties also in development for oral treatment of psoriasis and atopic dermatitis, for which a fast track designation has also been granted in atopic dermatitis.
UNION therapeutics today announced that the US FDA has granted fast track designation to oral orismilast for the treatment of moderate to severe hidradenitis suppurativa.
